Related references
Note: Only part of the references are listed.Improving maraviroc oral bioavailability by formation of solid drug nanoparticles
Alison C. Savage et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Towards a Maraviroc long-acting injectable nanoformulation
Lee M. Tatham et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era
Anis A. Hamid et al.
CLINICAL GENITOURINARY CANCER (2019)
Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice
Aditya Ambade et al.
HEPATOLOGY (2019)
CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury
Mary T. Joy et al.
CELL (2019)
Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy
Yan Nie et al.
CLINICAL CANCER RESEARCH (2019)
Mycosis Fungoides and Sezary Syndrome: An Update
Cecilia Larocca et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Efficacy and safety of long-term maraviroc use in a heterogeneous group of HIV-infected patients: A retrospective cohort study
J. M. Weehuizen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
Fedora Grande et al.
MOLECULES (2019)
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
Ravindra K. Gupta et al.
NATURE (2019)
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
Thomas A. Ollila et al.
ONCOTARGETS AND THERAPY (2019)
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5
Gen Nishikawa et al.
CELL DEATH & DISEASE (2019)
Involvement of CXCR4 in Normal and Abnormal Development
Nanako Kawaguchi et al.
CELLS (2019)
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
Daniela Francisci et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Yuan Cheng et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sezary Syndrome
Yvette L. Kasamon et al.
CLINICAL CANCER RESEARCH (2019)
A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma
Salma Afifi et al.
EXPERT OPINION ON DRUG SAFETY (2019)
CCR5 status and metastatic progression in colorectal cancer
Meggy Suarez-Carmona et al.
ONCOIMMUNOLOGY (2019)
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders
Laura Fantuzzi et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi et al.
CLINICAL CANCER RESEARCH (2019)
GENESIS: Phase III trial evaluating BL-8040+G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma
Zachary D. Crees et al.
FUTURE ONCOLOGY (2019)
The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro
Katrin Pansy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability
Fotios V. Michelis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
Naike Casagrande et al.
HAEMATOLOGICA (2019)
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
Adrienne A. Phillips et al.
HAEMATOLOGICA (2019)
WHIM syndrome: Immunopathogenesis, treatment and cure strategies
David H. McDermott et al.
IMMUNOLOGICAL REVIEWS (2019)
Adaptive Immunodeficiency in WHIM Syndrome
Shamik Majumdar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Structural basis of coreceptor recognition by HIV-1 envelope spike
Md Munan Shaik et al.
NATURE (2019)
Plerixafor for the Treatment of WHIM Syndrome
David H. McDermott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM
Ian McGowan et al.
AIDS (2019)
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
S. L. Pett et al.
HIV MEDICINE (2018)
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study
Jun Zhu et al.
TRANSFUSION (2018)
Pharmacogenomics of GPCR Drug Targets
Alexander S. Hauser et al.
CELL (2018)
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Frank Tacke
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
A guide to chemokines and their receptors
Catherine E. Hughes et al.
FEBS JOURNAL (2018)
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
Gail J. Roboz et al.
HAEMATOLOGICA (2018)
Hematopoietic stem cell mobilization with plerixafor in sickle cell disease
Matthew M. Hsieh et al.
HAEMATOLOGICA (2018)
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
Chantal Lagresle-Peyrou et al.
HAEMATOLOGICA (2018)
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel et al.
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism
Michelle L. D'Antoni et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise
Palak J. Trivedi et al.
JOURNAL OF CROHNS & COLITIS (2018)
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Maria Eugenia Guicciardi et al.
JOURNAL OF HEPATOLOGY (2018)
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Nadia Madrid-Elena et al.
JOURNAL OF VIROLOGY (2018)
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Sonia Pernas et al.
LANCET ONCOLOGY (2018)
Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
Tomoo Sato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
Carlo Giaquinto et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
The return of PRO 140, a CCR5-directed mAb
Melanie A. Thompson
CURRENT OPINION IN HIV AND AIDS (2018)
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
Gail J. Roboz et al.
HAEMATOLOGICA (2018)
Hematopoietic stem cell mobilization with plerixafor in sickle cell disease
Matthew M. Hsieh et al.
HAEMATOLOGICA (2018)
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
Chantal Lagresle-Peyrou et al.
HAEMATOLOGICA (2018)
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2
Natalia V. Ortiz Zacarias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
CCR4 Antagonists Inhibit Treg Trafficking into the Tumor Microenvironment
John M. Ketcham et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials
Marilyn Lewis et al.
PLOS ONE (2018)
Biased antagonism of CXCR4 avoids antagonist tolerance
Ben Hitchinson et al.
SCIENCE SIGNALING (2018)
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients
Erica B. Esrick et al.
BLOOD ADVANCES (2018)
Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
Ines Herrero-Fernandez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The evolution of stem-cell transplantation in multiple myeloma
Sarakshi Mahajan et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Pharmacogenetic considerations for HIV treatment in different ethnicities: an update
M. Neary et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist RevealsMechanisms of Chemokine Recognition and Molecular Mimicry by HIV
Yi Zheng et al.
IMMUNITY (2017)
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)
Ana Milinkovic et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Structural Analysis of Chemokine Receptor-Ligand Interactions
Marta Arimont et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial
Darja Karpova et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
M. Abraham et al.
LEUKEMIA (2017)
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)
Todd M. Cooper et al.
PEDIATRIC BLOOD & CANCER (2017)
Beyond Chemoattraction: Multifunctionality of Chemokine Receptors in Leukocytes
Pilar Lopez-Cotarelo et al.
TRENDS IN IMMUNOLOGY (2017)
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
G. L. Uy et al.
BLOOD CANCER JOURNAL (2017)
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Helen Ha et al.
THERANOSTICS (2017)
Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior
Xi Cheng et al.
SCIENTIFIC REPORTS (2017)
A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma
Satoshi Iyama et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals
Sergio Serrano-Villar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Michal Abraham et al.
CLINICAL CANCER RESEARCH (2017)
Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies
Takashi Ishida et al.
CANCER SCIENCE (2017)
Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates
Carolina Herrera et al.
AIDS (2016)
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Niels Halama et al.
CANCER CELL (2016)
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Sarah Lilian Pett et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activityof Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
E. Lefebvre et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Plerixafor for stem cell mobilization: the current status
Yavuz M. Bilgin et al.
CURRENT OPINION IN HEMATOLOGY (2016)
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists
Yi Zheng et al.
NATURE (2016)
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV
Guillaume Martin-Blondel et al.
NATURE REVIEWS NEUROLOGY (2016)
Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies
Anna Piotrowska et al.
NEUROPHARMACOLOGY (2016)
HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc
Himanshu Garg et al.
VIROLOGY (2016)
CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress
Yanyan Zhang et al.
SCIENTIFIC REPORTS (2016)
Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
Stefania Piconi et al.
SCIENTIFIC REPORTS (2016)
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naive to Antiretroviral Therapy: A Pilot Randomized Trial
Sergio Serrano-Villar et al.
PLOS PATHOGENS (2016)
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis
Amit C. Achhra et al.
LANCET HIV (2016)
Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice
Tao Liu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Plerixafor plus G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Garyfalia Karponi et al.
BLOOD (2015)
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Madeleine Duvic et al.
BLOOD (2015)
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation
M. Konopleva et al.
BONE MARROW TRANSPLANTATION (2015)
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study
Takashi Ishida et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Koji Kurose et al.
CLINICAL CANCER RESEARCH (2015)
Chemokine receptors as therapeutic targets: Why aren't there more drugs?
Roberto Solari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents
Juergen K. Rockstroh et al.
HIV CLINICAL TRIALS (2015)
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
Javier Garcia-Perez et al.
RETROVIROLOGY (2015)
Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Xiao Ni et al.
CLINICAL CANCER RESEARCH (2015)
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition
George Panos et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2015)
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
David A. Cooper et al.
AIDS (2014)
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor
David H. McDermott et al.
BLOOD (2014)
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy
S. K. Kumar et al.
BONE MARROW TRANSPLANTATION (2014)
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting
J. Macias et al.
HIV MEDICINE (2014)
Multicenter Phase II Study of Mogamulizumab ( KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Michinori Ogura et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4
Takashi Nagasawa
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
CYP3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers
Yanhui Lu et al.
DRUG METABOLISM AND DISPOSITION (2014)
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program
P. Shaughnessy et al.
BONE MARROW TRANSPLANTATION (2013)
Structure-Based Development of Antagonists for Chemokine Receptor CXCR4
Chongqian Zhang et al.
Current Computer-Aided Drug Design (2013)
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Urszula M. Domanska et al.
EUROPEAN JOURNAL OF CANCER (2013)
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial
Nigel Russell et al.
HAEMATOLOGICA (2013)
Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
Manoli Vourvahis et al.
HIV CLINICAL TRIALS (2013)
HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120
Annette N. Ratcliff et al.
JOURNAL OF VIROLOGY (2013)
Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues
Ivana Massud et al.
JOURNAL OF VIROLOGY (2013)
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
Qiuxiang Tan et al.
SCIENCE (2013)
Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
Florent Malard et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Efficacy and safety of hematopoietic stem cell remobilization with plerixafor plus G-CSF in adult patients with germ cell tumors
M. E. Horwitz et al.
BONE MARROW TRANSPLANTATION (2012)
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Hematopoietic Stem Cell Mobilization for Gene Therapy of Adult Patients With Severe beta-Thalassemia: Results of Clinical Trials Using G-CSF or Plerixafor in Splenectomized and Nonsplenectomized Subjects
Evangelia Yannaki et al.
MOLECULAR THERAPY (2012)
CCR10 and its ligands in regulation of epithelial immunity and diseases
Na Xiong et al.
PROTEIN & CELL (2012)
Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-Human Immunodeficiency Virus Drug Maraviroc
Yanhui Lu et al.
DRUG METABOLISM AND DISPOSITION (2012)
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation
Kristina Allers et al.
BLOOD (2011)
Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients
S. Kobold et al.
BONE MARROW TRANSPLANTATION (2011)
Plerixafor A Review of its Use in Stem-Cell Mobilization in Patients with Lymphoma or Multiple Myeloma
Gillian M. Keating
DRUGS (2011)
Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-negative Men
Kevin C. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience
Luca Arcaini et al.
LEUKEMIA RESEARCH (2011)
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program
Nina Worel et al.
TRANSFUSION (2011)
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Thomas J. Schall et al.
NATURE REVIEWS IMMUNOLOGY (2011)
A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment
Ronald MacFarland et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients
S. Fruehauf et al.
BONE MARROW TRANSPLANTATION (2010)
Maraviroc A Review of its Use in the Management of CCR5-Tropic HIV-1 Infection
Caroline M. Perry
DRUGS (2010)
Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
W. David Hardy et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients
Eduardo Seclen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
Kazuhito Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy
Allan R. Tenorio
Current HIV/AIDS Reports (2010)
Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient
Patrick Stiff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Douglas A. Stewart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio et al.
BLOOD (2009)
Plerixafor In Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma
Antona J. Wagstaff
DRUGS (2009)
Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women
Julie B. Dumond et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
John F. DiPersio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation
M. Abraham et al.
LEUKEMIA (2009)
OPINION Chemokine receptor antagonists: overcoming developmental hurdles
Richard Horuk
NATURE REVIEWS DRUG DISCOVERY (2009)
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
Samantha Abel et al.
ANTIVIRAL THERAPY (2009)
A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma
Amanda Cashen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
Steven M. Devine et al.
BLOOD (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
AMD3100 plus G-CSF can successfully mobilize CD34+cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data
G. Calandra et al.
BONE MARROW TRANSPLANTATION (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Defucosylated anti-CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory mycosis fungoides and Sezary syndrome
Hiroki Yano et al.
CLINICAL CANCER RESEARCH (2007)
Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4
Simon P. Fricker et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation
IF Charo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The geographic spread of the CCR5 Δ32 HIV-resistance allele
J Novembre et al.
PLOS BIOLOGY (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
N Flomenberg et al.
BLOOD (2005)
A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100
NA Lack et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
HE Broxmeyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist
WC Liles et al.
TRANSFUSION (2005)
Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor - Transfer of binding site to the CXCR3 receptor
MM Rosenkilde et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
CW Hendrix et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
WC Liles et al.
BLOOD (2003)
The bicyclam AMD3 100 story
E De Clercq
NATURE REVIEWS DRUG DISCOVERY (2003)
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
CW Hendrix et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
